An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP (ADOPT)

An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® (Avatrombopag) in Adult Patients With Immune Thrombocytopenia (ITP)

This is a multi-center, observational, Phase 4 study in patients with Immune Thrombocytopenia (ITP) designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base regarding the use of Doptelet in routine medical practice. Patients eligible for participation will, as part of their routine medical care, be receiving Doptelet for the treatment of ITP.

Study Overview

• Status: Completed
• Conditions: Immune Thrombocytopenia; ITP
• Intervention / Treatment: Drug: Avatrombopag

Detailed Description

This is a multi-center, observational, Phase 4 study in patients with ITP designed to describe the real-world effectiveness of Doptelet and assess the patterns of drug utilization to add to the knowledge base regarding the use of Doptelet in routine medical practice.

Patients eligible for participation will, as part of their routine medical care, be receiving Doptelet for the treatment of ITP.

The scope of the study is to collect both retrospective and prospective data. The main part of the study will be prospective collecting data on usage, effectiveness, safety, patient- and clinician-reported outcomes and health economic parameters whereas the retrospective part will consist of collection of information on previous treatments, reason for treatment switch, healthcare resource use and, if applicable, Doptelet treatment prior to enrollment. The retrospective data collection will be based on the information available in the patient's medical records. Data will be collected for up to 12 months prior to Doptelet treatment start.

Prospective data will be collected at routine clinical visits throughout the study. Patients will be followed for 12 (+6) months and will be enrolled until their first scheduled visit after 12 months of enrollment, or until early termination, whichever occurs first.

• Study Type: Observational
• Enrollment (Actual): 199

Contacts and Locations

Study Locations

• Croatia
  • Zagreb, Croatia
    • Swedish Orphan Biovitrum Research Site 131
• Czechia
  • Brno, Czechia
    • Swedish Orphan Biovitrum Research Site 122
  • Ostrava, Czechia
    • Swedish Orphan Biovitrum Research Site 123
  • Praha, Czechia
    • Swedish Orphan Biovitrum Research Site 121
  • Praha, Czechia
    • Swedish Orphan Biovitrum Research Site 124
  • Praha, Czechia
    • Swedish Orphan Biovitrum Research Site 125
• Germany
  • Aschaffenburg, Germany
    • Swedish Orphan Biovitrum Research Site 108
  • Augsburg, Germany
    • Swedish Orphan Biovitrum Research Site 114
  • Augsburg, Germany
    • Swedish Orphan Biovitrum Research Site 116
  • Bad Homburg, Germany
    • Swedish Orphan Biovitrum Research Site 103
  • Berlin, Germany
    • Swedish Orphan Biovitrum Research Site 106
  • Dresden, Germany
    • Swedish Orphan Biovitrum Research Site 113
  • Frankfurt, Germany
    • Swedish Orphan Biovitrum Research Site 102
  • Frankfurt, Germany
    • Swedish Orphan Biovitrum Research Site 105
  • Hannover, Germany
    • Swedish Orphan Biovitrum Research Site 104
  • Kaiserslautern, Germany
    • Swedish Orphan Biovitrum Research Site 112
  • Kassel, Germany
    • Swedish Orphan Biovitrum Research Site 101
  • Leipzig, Germany
    • Swedish Orphan Biovitrum Research Site 115
  • Schorndorf, Germany
    • Swedish Orphan Biovitrum Research Site 109
  • Stolberg, Germany
    • Swedish Orphan Biovitrum Research Site 111
• Italy
  • Bologna, Italy
    • Swedish Orphan Biovitrum Research Site 509
  • Catania, Italy
    • Swedish Orphan Biovitrum Research Site 504
  • Firenze, Italy
    • Swedish Orphan Biovitrum Research Site 502
  • Meldola, Italy
    • Swedish Orphan Biovitrum Research Site 506
  • Milan, Italy
    • Swedish Orphan Biovitrum Research Site 511
  • Milano, Italy
    • Swedish Orphan Biovitrum Research Site 510
  • Roma, Italy
    • Swedish Orphan Biovitrum Research Site 503
  • Rome, Italy
    • Swedish Orphan Biovitrum Research Site 505
• Netherlands
  • Apeldoorn, Netherlands, 7334 DZ
    • Swedish Orphan Biovitrum Research Site 202
  • Arnhem, Netherlands
    • Swedish Orphan Biovitrum Research Site 204
  • Den Haag, Netherlands
    • Swedish Orphan Biovitrum Research Site 203
• Norway
  • Bergen, Norway
    • Swedish Orphan Biovitrum Research Site 302
  • Oslo, Norway
    • Swedish Orphan Biovitrum Research Site 301
• Spain
  • Barcelona, Spain
    • Swedish Orphan Biovitrum Research Site 611
  • Burgos, Spain
    • Swedish Orphan Biovitrum Research Site 609
  • Granada, Spain
    • Swedish Orphan Biovitrum Research Site 610
  • Madrid, Spain
    • Swedish Orphan Biovitrum Research Site 601
  • Madrid, Spain
    • Swedish Orphan Biovitrum Research Site 605
  • Murcia, Spain
    • Swedish Orphan Biovitrum Research Site 607
  • Oviedo, Spain
    • Swedish Orphan Biovitrum Research Site 606
  • Palma De Mallorca, Spain
    • Swedish Orphan Biovitrum Research Site 608
  • Salamanca, Spain
    • Swedish Orphan Biovitrum Research Site 602
  • Sevilla, Spain
    • Swedish Orphan Biovitrum Research Site 604
  • Vigo, Spain
    • Swedish Orphan Biovitrum Research Site 603
• Switzerland
  • Basel, Switzerland
    • Swedish Orphan Biovitrum Research Site 802
  • Lausanne, Switzerland
    • Swedish Orphan Biovitrum Research Site 801
• United Kingdom
  • Bristol, United Kingdom
    • Swedish Orphan Biovitrum Research Site 701
  • Leicester, United Kingdom
    • Swedish Orphan Biovitrum Research Site 704
  • London, United Kingdom
    • Swedish Orphan Biovitrum Research Site 707
  • London, United Kingdom
    • Swedish Orphan Biovitrum Research Site 710
  • Newcastle, United Kingdom
    • Swedish Orphan Biovitrum Research Site 705
  • Nottingham, United Kingdom
    • Swedish Orphan Biovitrum Research Site 702
  • Oxford, United Kingdom
    • Swedish Orphan Biovitrum Research Site 703
  • Scotland
    • Edinburgh, Scotland, United Kingdom
      • Swedish Orphan Biovitrum Research Site 709
    • Glasgow, Scotland, United Kingdom
      • Swedish Orphan Biovitrum Research Site 708

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The Investigators will attempt to consecutively enroll all eligible patients who present for a routine clinical visit or during a routine visit where the patient is started on Doptelet treatment (new users of Doptelet).

Description

Inclusion Criteria:

1. Patient is ≥18 years of age
2. Established and well documented ITP diagnosis
3. Patient is treated with, or at enrollment prescribed, Doptelet for ITP. Decision to initiate treatment shall be made by the treating physician and independently from the decision to include the patient in the study
4. Signed and dated informed consent provided by the patient before any study-related activities are undertaken
5. Willing and able to comply with protocol requirements

Exclusion Criteria:

1. Enrollment in a concurrent clinical interventional study, or intake of an Investigational Medicinal Product (IMP), within three months prior to inclusion in this study
2. ITP secondary to Evan's syndrome, lupus and other autoimmune diseases
3. ITP secondary to other hematological disorders and hematological malignancies
4. ITP secondary to any other malignancies
5. ITP secondary to known drug toxicity
6. ITP secondary to any other disease considered relevant by the Investigator

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Other

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Full-analysis set (FAS); The FAS includes all enrolled patients. The FAS will be used for all analyses.	Drug: Avatrombopag; According to prescription; Other Names: Doptelet®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative number of weeks with a platelet count ≥30×109/L during Doptelet treatment.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results. Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP. Platelet counts during rescue medication use and within 4 weeks after stopping a rescue medication or following splenectomy will not be counted in the cumulative number of weeks.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cumulative number of weeks with a platelet count ≥50×109/L during Doptelet treatment.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results. Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP. Platelet counts during rescue medication use and within 4 weeks after stopping a rescue medication or following splenectomy will not be counted in the cumulative number of weeks.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Number and proportion of patients with a platelet count ≥30×109/L, for at least 8 consecutive weeks.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Number and proportion of patients with a platelet count ≥50×109/L for at least 8 consecutive weeks.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Number and proportion of patients experiencing WHO bleeding grade ≥ 2.	All bleeding events will be assessed by the Investigator according to the WHO bleeding scale where the severity of the bleeding is graded from 0 to 4 (0=no bleeding; 1=petechial bleeding; 2=mild blood loss (clinically significant); 3=gross blood loss; requires transfusion (severe); 4=debilitating blood loss, retinal or cerebral associated with fatality).	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Number and proportion of patients requiring rescue medication.	Information will be collected via the patient's medical records.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Time from Doptelet treatment start to platelet count ≥30×109/L.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Time from Doptelet treatment start to platelet count ≥50×109/L.	Laboratory measures of platelet count will be collected if performed according to routine clinical practice and available in the patient's medical records. All analyses of platelet counts will be based on local laboratory results.Platelet count is an accepted surrogate marker for bleeding risk. Platelet count is a standard measurement commonly used both in clinical practice and in studies in patients with ITP.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Doptelet dose and dosing frequency per patient (assessed by prescription).	Information will be collected via the patient's medical records.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Reason for ITP treatment discontinuation or change from one ITP treatment to another, prior to as well as during the study.	Information will be collected via the patient's medical records.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Patient satisfaction with outcome of Doptelet treatment using the Treatment Satisfaction Questionnaire for Medication (TSQM-9).	TSQM-9 is a self-administered generic measure to assess patients' satisfaction with their medication. It consists of nine items distributed across three dimensions: Effectiveness (3 items), Convenience (3 items) and Global satisfaction scale (3 items). Each domain score ranges from 0 to 100, higher score indicating greater satisfaction.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Physician satisfaction with outcome of Doptelet treatment using a 5 point scale.	The treating physician will evaluate satisfaction with the Doptelet treatment by answering the question: "On a scale of 1-5 with 5 being highly satisfied and 1 being highly dissatisfied, how would you rate your satisfaction with the desired treatment outcome of the Doptelet treatment?"	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Physician assessment of clinical change of Doptelet treatment using the Clinical Global Impression of Change (CGIC) scale.	The treating physician will evaluate the clinical change of Doptelet treatment by grading the change on a 7-point scale; very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Change from enrollment in the European Quality of Life - 5 Dimensions (EQ-5D-5L) scale.	The EQ-5D is a standardized generic instrument for use as a measure of health outcome. The EQ-5D consists of 2 parts - the EQ-5D descriptive profile which is mapped into a single index value for health status (utility value) and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Change from enrollment in the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire (ITP-PAQ).	ITP-PAQ is a disease-specific self-administered tool which was developed and validated to assess health related quality of life (HRQoL) in adult patients with ITP using a 4-week recall period. It consists in 44 items distributed across 10 dimensions: Symptoms (6 items), Bother-Physical Health (3 items), Fatigue/Sleep (4 items), Activity (2 items), Fear (5 items), Psychological Health (5 items), Work (4 items), Social Activity (4 items), Women's Reproductive Health (6 items) and Overall QoL (5 items). Each scale is scored from 0 to 100, with higher scores representing better HRQoL.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Change from enrollment in the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) questionnaire.	FACIT-Fatigue is a 13-item scale developed to assess specifically quality of life concerns related to fatigue in patients with chronic diseases. The scale was initially developed to assess cancer-related fatigue, however it has been since then used and psychometrically validated in other chronic diseases, including ITP. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning over the past seven days. Each item is scored on a 5-point Likert Scale ranging from "0-Not at all" to "4-Very much".	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Change from enrollment in Patient Global Impression of Change (PGIC) scale.	PGIC will be used to evaluate patients' perception of changes in the severity of their ITP symptoms on the scale: very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Change from enrollment in Work Productivity and Activity Impairment (WPAI) questionnaire.	WPAI for specific health problem, WPAI:SHP v2.0 questionnaire is a generic and standard instrument developed to measure the effect of specific health problems and symptom severity on work productivity and regular activities during the past seven days. It contains six items which ascertain employment status and quantify absenteeism due to health problems, presenteeism and overall health-related impairment in both paid work and regular activities over the previous 7 days. The WPAI provides quantitative data at the item level compatible with economic modelling.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Healthcare resource use including; Inpatient and /or outpatient visits since last routine visit.	The following data related to in-patient and/or out-patient visits since last routine visit will be collected: Length of hospitalization; Reason for visit; Surgical procedures; ICU stay, CT scans; Regular blood tests and haemato-chemistry blood tests; Platelet transfusions; Other.	Data will be collected retrospectively via the medical records for a time period of 12 months prior to Doptelet start as well as prospectively for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Use of concomitant ITP medications throughout the study.	Information will be collected via the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Serious adverse events (SAEs)	Information will be collected via reports from the Investigators based on the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Adverse events of special interest (AESIs) (e.g., thromboembolic events, significant bleeding (WHO bleeding scale grade ≥ 3)).	Information will be collected via reports from the Investigators based on the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
AEs leading to Doptelet discontinuation.	Information will be collected via reports from the Investigators based on the patient's medical records.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.
Adherence to Doptelet treatment assessed via the 8-item Morisky Medication Adherence Scale (MMAS-8).	MMAS-8 is an 8-item structured, self-reported medication adherence measure. The self-reported measure of medication taking was developed from a previously validated 4-item scale and supplemented with additional items addressing the circumstances surrounding adherence behavior. Each item measures a specific medication-taking behavior and not a determinant of adherence behavior. Response categories are yes/no for each item with a dichotomous response and a 5-point Likert response for the last item. Adherent patients are identified with the score of 8 on the scale, medium adherers with a score of 6 to <8, and low adherers with a score of <6. The MMAS-8 Scale, content, name, and trademarks are protected by US copyright and trademark laws. Permission for use of the scale and its coding is required. A license agreement is available from Donald E. Morisky, ScD, ScM, MSPH; donald.morisky@moriskyscale.com.	Data will be collected for all routine visits completed during the study period which is at least 12 but not more than 18 months.

Collaborators and Investigators

• Sponsor: Swedish Orphan Biovitrum
• Investigators: Study Director: Nina Skuban, MD, Swedish Orphan Biovitrum AB; Study Director: Vickie McDonald, MD, Royal London Hospital, London, UK

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2022
• Primary Completion (Actual): June 10, 2025
• Study Completion (Actual): June 10, 2025

Study Registration Dates

• First Submitted: June 21, 2021
• First Submitted That Met QC Criteria: June 21, 2021
• First Posted (Actual): June 29, 2021

Study Record Updates

• Last Update Posted (Actual): July 14, 2025
• Last Update Submitted That Met QC Criteria: July 11, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: TPO RA (thrombopoietin receptor agonists )
• Additional Relevant MeSH Terms: Cytopenia; Pathologic Processes; Autoimmune Diseases; Immune System Diseases; Hemorrhage; Skin Manifestations; Hematologic Diseases; Blood Coagulation Disorders; Hemorrhagic Disorders; Blood Platelet Disorders; Thrombotic Microangiopathies; Purpura, Thrombocytopenic; Purpura; Thrombocytopenia; Purpura, Thrombocytopenic, Idiopathic
• Other Study ID Numbers: Sobi.Doptelet-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: According to Sobi's data sharing policy Sobi may share anonymized clinical study data with qualified researchers. Sobi commits to sharing clinical study data on participant level and summary data for medicines and indications approved by the European Medicines Agency (EMA) and/or the Food and Drug Administration (FDA). Data access will be granted in response to qualified research requests. All requests are evaluated by a cross functional panel of experts within Sobi.
• IPD Sharing Time Frame: Evaluated on a case by case basis

IPD Sharing Access Criteria

A decision on data sharing will be based on the following:

• The scientific merit of the proposal - i.e. the proposal should be scientifically sound, ethical, and have the potential to contribute to the advancement of public health.
• The feasibility of the research proposal - i.e. the requesting research team must be scientifically qualified and have the resources to conduct the proposed project.
• Maintenance of personal integrity - i.e. Sobi will not consider sharing individual data if there is a risk of re-identification of individuals despite a proper anonymisation. Moreover, the patients' informed consent will always be respected. Sobi reserves the right to reject the proposal if the anonymisation process will render unusable data.
• Publication of results - the applicants should commit to submit their findings to a peer-reviewed scientific journal, alternatively to present the results at a congress (poster or similar), regardless of the research outcome.